Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
BLX 0.57ELF.TO 0.09RY.TO 3.05PEY.TO 0.26CP.TO -0.12BRK.B -0.57MSFT -5.93META 6.73
Stryker Corp. (SYK)

NYSE:SYK

Stryker Corp. (SYK)

310.58
+2.64 (0.86%)
as of Jun 16, 2026, 8:00:00 pm Market Open.
258 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 16, 2026, 12:00 am

This summary was created by AI, based on 6 opinions in the last 12 months.

Stryker Corp. (SYK) has experienced volatility in its stock price due to challenges in the healthcare sector and a recent cybersecurity incident. However, experts remain optimistic about the company’s long-term prospects, particularly in orthopedics, where it has a strong market position and good relationships with healthcare professionals. The aging population is expected to drive demand for orthopedic surgeries, enhancing Stryker’s growth potential. Analysts project a significant increase in earnings per share over the next few years, and while there is a consensus that investing may not be timely right now, the company is viewed positively for its strong management and growth capabilities in the medical device market.

consensus icon
Consensus
Positive
valuation icon
Valuation
Undervalued
review icon
Similar
Medtronic,MDT
BUY

Stryker Corp.(SYK)

Feb 11, 2020
Medical devices are a good play on aging US demographics. SYK recently merged with a smaller company to consolidate their hips and knees products. He owns its peers including Boston Scientific, but the whole space is enjoying a nice upside. You can buy SYK.
Photo of Jamie Murray Jamie Murray
No
Unlock Rating
$217.68

Stock price when the opinion was issued

$310.58

As of Jun 16, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
BUY

Stryker Corp.(SYK)

Feb 06, 2020
Joint replacements. Medical instruments. Great company. Issues with latest acquisition, so stock fell below its high.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$218.24

Stock price when the opinion was issued

$310.58

As of Jun 16, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Stryker Corp.(SYK)

Jan 29, 2020

SYK vs. Anthem He likes both. Stryker trades at 23x PE. He owns Anthem, which hit on earnings, but the market was skittish on their expense line. It's a great healthcare company

Photo of Gordon ReidGordon Reid
No
Unlock Rating
$210.68

Stock price when the opinion was issued

$310.58

As of Jun 16, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

Jan 20, 2020
(A Top Pick Jan 04/19, Up 21%) The best, most innovative medical device company around. It's come off its highs recently as it acquired a spinal business, but it has room to run. It's long grown its earnings for many years. They excel at buying small companies specializing in hips, knees and spines.
Photo of John O'Connell, CFAJohn O'Connell, CFA
Owned
Unlock Rating
$212.17

Stock price when the opinion was issued

$310.58

As of Jun 16, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Jan 17, 2020
A diversified medical devices company. They create a variety of equipment, including orthopaedics and robotic surgery. The company has executed very well. They recently made an acquisition that helps them move into hips, knees and ankles. There is volatility. He would enter around $205-210. (Analysts’ price target is $230.25)
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$212.17

Stock price when the opinion was issued

$310.58

As of Jun 16, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Dec 19, 2019
Good demographic growth--people are getting older and need hip and knee replacement. They just bought a company that will make SYK the biggest company serving hands and ankles. Another plus is that doctors tend to stick with the same medical product manufacturers. They have $3 billion in free cash and pays a nice dividend. They constantly buy companies, but their debt is fine. (Analysts’ price target is $231.08)
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$208.08

Stock price when the opinion was issued

$310.58

As of Jun 16, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Stryker Corp.(SYK)

Dec 18, 2019

SYK vs. JNJ SYK makes medical products while JNJ also produces that plus pharma and personal care products, but are fighting talcum powder lawsuits that will persist. Despite this, he much prefers JNJ due to better diversification and valuation. But wait for a better entry point.

Photo of Lorne SteinbergLorne SteinbergUnlock Rating
$208.52

Stock price when the opinion was issued

$310.58

As of Jun 16, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Nov 27, 2019
Diversified in orthopedics and medical instruments. Zimmer falling on hard times has been to its benefit. Not that expensive, around 20x earnings. Likes it.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$204.94

Stock price when the opinion was issued

$310.58

As of Jun 16, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
PAST TOP PICK

Stryker Corp.(SYK)

Nov 07, 2019
(A Top Pick Nov 20/18, Up 22%) Demographically, in a great spot. Recent acquisition will expand their market. Developing robotics. Positive long-term.
Photo of Zachary Curry Zachary Curry
Owned
Unlock Rating
$200.78

Stock price when the opinion was issued

$310.58

As of Jun 16, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Oct 28, 2019
They don't have the patent cliffs that the drugs are going to come off, and they will continue to innovate. Aging demographics will help demand. He's happy to hold this.
Photo of Brett Girard, CPA, CA, CFABrett Girard, CPA, CA, CFA
Owned
Unlock Rating
$213.72

Stock price when the opinion was issued

$310.58

As of Jun 16, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Jul 17, 2019
One of his favourite medtech names. They lead in robotic surgery. Great organic growth. They're setting up for a great quarter.
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$207.95

Stock price when the opinion was issued

$310.58

As of Jun 16, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Jun 27, 2019
The medical device sector has been a leading group for the last three years and he has been a big proponent. They are interesting because it is secular growth. Demographics support what these companies are doing. They are very defensible because they are not tied to the economic cycle. So long as growth performs well, he likes this group. He owns it through the medical devices ETF.
Photo of David BurrowsDavid Burrows
Owned
Unlock Rating
$202.54

Stock price when the opinion was issued

$310.58

As of Jun 16, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

Jun 21, 2019
(A Top Pick Aug 17/18, Up 20%) Hips and knees. Robots doing knee surgery. 3D replacements for hips. Continues to chug along. Growing revenue 6-7%.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$202.72

Stock price when the opinion was issued

$310.58

As of Jun 16, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Jun 04, 2019

Medical devices in a great demographic growth area. They are developing robotics to assist in surgery. Think of it as a med-tech company. Yield 1.1% (Analysts’ price target is $201.12)

Photo of Zachary Curry Zachary Curry
Owned
Unlock Rating
$186.45

Stock price when the opinion was issued

$310.58

As of Jun 16, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

May 21, 2019
Medical devices company. Great company. Will continue to grow with the aging population. 73% of the business in the U.S., 23% in Europe and the rest emerging markets. Can grow their business internationally. Very little debt. Great story, great growth and operating margins. (Analysts’ price target is $201.12)
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$185.45

Stock price when the opinion was issued

$310.58

As of Jun 16, 2026. Market Open.

biotechnologypharmaceutical
Showing 91 to 105 of 170 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

AVGO -17.23$376.71
CCO.TO 1.26$151.04
TOU.TO -0.47$60.79
BTE.TO -0.22$5.91
ADM -1.25$78.02

Today's Top Picks

BLX 0.57$59.24
ELF.TO 0.09$16.98
RY.TO 3.05$281.51
PEY.TO 0.26$24.91
CP.TO -0.12$124.8

Popular Articles

Latest Sell Signals

OTEX.TO 0.14$30.96
BSX 0.16$46.92
GIL.TO -16.24$70.39
SHOP.TO 1.22$158.49
WCN.TO 3.21$219.59

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica